KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Other Non-Current Liabilities: 2015-2024

Historic Other Non-Current Liabilities for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $66.7 million.

  • BeOne Medicines' Other Non-Current Liabilities rose 26.67% to $64.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.1 million, marking a year-over-year increase of 26.67%. This contributed to the annual value of $66.7 million for FY2024, which is 31.34% up from last year.
  • Per BeOne Medicines' latest filing, its Other Non-Current Liabilities stood at $66.7 million for FY2024, which was up 31.34% from $50.8 million recorded in FY2023.
  • BeOne Medicines' Other Non-Current Liabilities' 5-year high stood at $180.5 million during FY2022, with a 5-year trough of $50.8 million in FY2023.
  • Its 3-year average for Other Non-Current Liabilities is $99.3 million, with a median of $66.7 million in 2024.
  • Per our database at Business Quant, BeOne Medicines' Other Non-Current Liabilities spiked by 232.77% in 2022 and then crashed by 71.85% in 2023.
  • BeOne Medicines' Other Non-Current Liabilities (Yearly) stood at $57.4 million in 2020, then decreased by 5.56% to $54.2 million in 2021, then surged by 232.77% to $180.5 million in 2022, then plummeted by 71.85% to $50.8 million in 2023, then surged by 31.34% to $66.7 million in 2024.